BRCA1/2突变-话题@MedSci

#BRCA1/2突变#

10篇内容 | 584人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1621454, encodeId=ff82162145499, content=<a href='/topic/show?id=1c3b36890d' target=_blank style='color:#2F92EE;'>#BRCA1/2突变#</a>, objectTitle=Lancet Oncol：鲁卡帕利可作为BRCA1/2突变的复发性卵巢癌化疗的替代选择, objectType=article, longId=300992, objectId=cea030099207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cea030099207, replyNumber=0, likeNumber=43, createdTime=2022-03-18, rootId=0, userName=jiyangfei, userId=085920261380, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cea030099207, moduleTitle=Lancet Oncol：鲁卡帕利可作为BRCA1/2突变的复发性卵巢癌化疗的替代选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cea030099207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621453, encodeId=d1f8162145303, content=<a href='/topic/show?id=1c3b36890d' target=_blank style='color:#2F92EE;'>#BRCA1/2突变#</a>, objectTitle=BRCA1/2突变的年轻患者是否适宜保乳手术？, objectType=article, longId=213883, objectId=856a2138838e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=856a2138838e, replyNumber=0, likeNumber=39, createdTime=2021-07-09, rootId=0, userName=jiyangfei, userId=085920261380, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=856a2138838e, moduleTitle=BRCA1/2突变的年轻患者是否适宜保乳手术？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=856a2138838e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621452, encodeId=41651621452cb, content=<a href='/topic/show?id=1c3b36890d' target=_blank style='color:#2F92EE;'>#BRCA1/2突变#</a>, objectTitle=BRCA1/2突变铂敏感型复发性卵巢癌：奥拉帕利较非铂化疗能有效改善PFS, objectType=article, longId=206058, objectId=87ad20605893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87ad20605893, replyNumber=0, likeNumber=45, createdTime=2021-01-24, rootId=0, userName=jiyangfei, userId=085920261380, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87ad20605893, moduleTitle=BRCA1/2突变铂敏感型复发性卵巢癌：奥拉帕利较非铂化疗能有效改善PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87ad20605893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621451, encodeId=2fab16214519a, content=<a href='/topic/show?id=1c3b36890d' target=_blank style='color:#2F92EE;'>#BRCA1/2突变#</a>, objectTitle=Eur J Cancer：BRCA1/2突变对三阴性乳腺癌新辅助化疗时发生严重血液毒性风险的影响, objectType=article, longId=205690, objectId=826020569015, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=826020569015, replyNumber=0, likeNumber=38, createdTime=2021-01-14, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=826020569015, moduleTitle=Eur J Cancer：BRCA1/2突变对三阴性乳腺癌新辅助化疗时发生严重血液毒性风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=826020569015)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621450, encodeId=5766162145083, content=<a href='/topic/show?id=1c3b36890d' target=_blank style='color:#2F92EE;'>#BRCA1/2突变#</a>, objectTitle=Brit J Cancer：IVF卵巢刺激与BRCA1/2突变携带者原发性乳腺癌风险！, objectType=article, longId=141707, objectId=f022141e0757, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f022141e0757, replyNumber=0, likeNumber=0, createdTime=2018-06-28, rootId=0, userName=jiyangfei, userId=085920261380, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f022141e0757, moduleTitle=Brit J Cancer：IVF卵巢刺激与BRCA1/2突变携带者原发性乳腺癌风险！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f022141e0757)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621449, encodeId=4b6d1621449c5, content=<a href='/topic/show?id=1c3b36890d' target=_blank style='color:#2F92EE;'>#BRCA1/2突变#</a>, objectTitle=Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究, objectType=article, longId=137196, objectId=7db713e1967a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7db713e1967a, replyNumber=0, likeNumber=38, createdTime=2018-05-05, rootId=0, userName=jiyangfei, userId=085920261380, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7db713e1967a, moduleTitle=Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7db713e1967a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621448, encodeId=5086162144868, content=<a href='/topic/show?id=1c3b36890d' target=_blank style='color:#2F92EE;'>#BRCA1/2突变#</a>, objectTitle=Lancet Oncol：奥拉帕尼片剂可用于铂敏感、复发性卵巢癌及BRCA1/2突变(SOLO2/ENGOT-Ov21/)患者的维持治疗, objectType=article, longId=106877, objectId=eba21068e7a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eba21068e7a6, replyNumber=0, likeNumber=0, createdTime=2017-07-28, rootId=0, userName=jiyangfei, userId=085920261380, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eba21068e7a6, moduleTitle=Lancet Oncol：奥拉帕尼片剂可用于铂敏感、复发性卵巢癌及BRCA1/2突变(SOLO2/ENGOT-Ov21/)患者的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eba21068e7a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621447, encodeId=5c72162144ed6, content=<a href='/topic/show?id=1c3b36890d' target=_blank style='color:#2F92EE;'>#BRCA1/2突变#</a>, objectTitle=JAMA:BRCA1/2突变携带者，不同年龄阶段的患癌风险到底有多大？, objectType=article, longId=103121, objectId=6c24103121f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c24103121f0, replyNumber=0, likeNumber=31, createdTime=2017-06-25, rootId=0, userName=jiyangfei, userId=085920261380, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c24103121f0, moduleTitle=JAMA:BRCA1/2突变携带者，不同年龄阶段的患癌风险到底有多大？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c24103121f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621446, encodeId=77c61621446d4, content=<a href='/topic/show?id=1c3b36890d' target=_blank style='color:#2F92EE;'>#BRCA1/2突变#</a>, objectTitle=Breast Cancer Res Treat：中国乳腺癌女性BRCA1/2突变研究, objectType=article, longId=73659, objectId=41cfe365904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41cfe365904, replyNumber=0, likeNumber=33, createdTime=2016-07-26, rootId=0, userName=jiyangfei, userId=085920261380, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41cfe365904, moduleTitle=Breast Cancer Res Treat：中国乳腺癌女性BRCA1/2突变研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41cfe365904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621445, encodeId=ef16162144511, content=<a href='/topic/show?id=1c3b36890d' target=_blank style='color:#2F92EE;'>#BRCA1/2突变#</a>, objectTitle=JCO:口服避孕药不降低BRCA1/2突变携带者的卵巢癌及乳腺癌风险, objectType=article, longId=26026, objectId=cd98260269f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd98260269f, replyNumber=0, likeNumber=22, createdTime=2013-11-02, rootId=0, userName=jiyangfei, userId=085920261380, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd98260269f, moduleTitle=JCO:口服避孕药不降低BRCA1/2突变携带者的卵巢癌及乳腺癌风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd98260269f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BRCA1/2突变

2020-05-29

jiyangfei (审核中...)

前往app查看评论内容

#BRCA1/2突变#

Lancet Oncol：鲁卡帕利可作为BRCA1/2突变的复发性卵巢癌化疗的替代选择

2022-03-18

jiyangfei (审核中...)

前往app查看评论内容

#BRCA1/2突变#

BRCA1/2突变的年轻患者是否适宜保乳手术？

2021-07-09

jiyangfei (审核中...)

前往app查看评论内容

#BRCA1/2突变#

BRCA1/2突变铂敏感型复发性卵巢癌：奥拉帕利较非铂化疗能有效改善PFS

2021-01-24

医者仁心 (审核中...)

前往app查看评论内容

#BRCA1/2突变#

Eur J Cancer：BRCA1/2突变对三阴性乳腺癌新辅助化疗时发生严重血液毒性风险的影响

2021-01-14

jiyangfei (审核中...)

前往app查看评论内容

#BRCA1/2突变#

Brit J Cancer：IVF卵巢刺激与BRCA1/2突变携带者原发性乳腺癌风险！

2018-06-28

jiyangfei (审核中...)

前往app查看评论内容

#BRCA1/2突变#

Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究

2018-05-05

jiyangfei (审核中...)

前往app查看评论内容

#BRCA1/2突变#

Lancet Oncol：奥拉帕尼片剂可用于铂敏感、复发性卵巢癌及BRCA1/2突变(SOLO2/ENGOT-Ov21/)患者的维持治疗

2017-07-28

jiyangfei (审核中...)

前往app查看评论内容

#BRCA1/2突变#

JAMA:BRCA1/2突变携带者，不同年龄阶段的患癌风险到底有多大？

2017-06-25

jiyangfei (审核中...)

前往app查看评论内容

#BRCA1/2突变#

Breast Cancer Res Treat：中国乳腺癌女性BRCA1/2突变研究

2016-07-26

jiyangfei (审核中...)

前往app查看评论内容

#BRCA1/2突变#

JCO:口服避孕药不降低BRCA1/2突变携带者的卵巢癌及乳腺癌风险

2013-11-02

科室
- - 订阅+
  - 更多科室
工具
服务